Literature DB >> 3761287

Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.

D J Evans, C W Burke.   

Abstract

Forty-eight hirsute women were treated with spironolactone 100 mg twice daily for 3 to 12 months. Both facial and body hirsuties improved by 30-40%, and there was a threefold reduction in frequency of local treatments such as waxing or shaving. Plasma testosterone fell by 30%, though the improvement in hirsuties grading did not correlate with the fall in plasma testosterone. Six subjects discontinued treatment because of lack of effect, and 4 because of menstrual disturbance. Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3761287      PMCID: PMC1290413          DOI: 10.1177/014107688607900806

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  16 in total

1.  Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  JAMA       Date:  1973-07-02       Impact factor: 56.272

2.  The effect of spironolactone on hirsutism and female androgen metabolism.

Authors:  P Dorrington-Ward; A C McCartney; S Holland; J Scully; G Carter; J Alaghband-Zadeh; P Wise
Journal:  Clin Endocrinol (Oxf)       Date:  1985-08       Impact factor: 3.478

3.  Spironolactone therapy for hirsutism in a hyperandrogenic woman.

Authors:  K P Ober; J F Hennessy
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

4.  New therapeutic approach to the hirsute patient.

Authors:  A Boisselle; R R Tremblay
Journal:  Fertil Steril       Date:  1979-09       Impact factor: 7.329

5.  Interaction of spironolactone with rat skin androgen receptor.

Authors:  A Boisselle; F T Dionne; R R Tremblay
Journal:  Can J Biochem       Date:  1979-07

6.  Treatment of hirsutism with spironolactone.

Authors:  D C Cumming; J C Yang; R W Rebar; S S Yen
Journal:  JAMA       Date:  1982-03-05       Impact factor: 56.272

7.  Therapeutic effects of spironolactone in polycystic ovary syndrome.

Authors:  A Milewicz; D Silber; M A Kirschner
Journal:  Obstet Gynecol       Date:  1983-04       Impact factor: 7.661

8.  Spironolactone and endocrine dysfunction.

Authors: 
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391

9.  A novel use of spironolactone: treatment of hirsutism.

Authors:  G Shapiro; S Evron
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

10.  Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.

Authors:  M Messina; C Manieri; P Biffignandi; C Massucchetti; R F Novi; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

View more
  4 in total

1.  Calculating confidence intervals for some non-parametric analyses.

Authors:  M J Campbell; M J Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

Review 2.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

Review 3.  Alopecia and hirsuties. Current concepts in pathogenesis and management.

Authors:  J H Barth
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

4.  Lack of effect of spironolactone on hair shaft diameter in hirsute females.

Authors:  A R McLellan; J Rentoul; R MacKie; G T McInnes
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.